Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Gastroenterology. 2012 Jan 4;142(4):844–854.e4. doi: 10.1053/j.gastro.2011.12.041

Figure 5.

Figure 5

(A) Tegaserod (1 μmol/L) caused a significant increase in ISC that was blocked by the 5-HT4R antagonist, GR113808 (1 μmol/L), and by neural blockade with TTX (0.3 μmol/L). (B) Serosal application of tegaserod did not alter the ISC. (C) No response was detected by mucosal application of tegaserod in the duodenum. ***P < .001 vs vehicle; †P < .001 vs tegaserod (n = 6).